港股異動 | 愛康醫療(1789.HK)跌超5% 2021年純利減少70.5%至9262萬元
格隆匯3月25日丨愛康醫療(1789.HK)跌超5%,報4.49港元,總市值50億港元。愛康醫療發佈公吿,截至2021年12月31日止年度,公司收入7.61億元人民幣,同比減少26.5%;公司權益股東應占年度溢利9262萬元,同比減少70.5%;每股盈利人民幣0.08元,派付末期股息每股股份2.5港仙。收入下降主要是歸因於現行全國關節植入物帶量採購政策下價格下跌導致經銷商(即集團客户)為減少庫存而減少採購關節植入物,以及為若干特定關節植入物作出未來銷售價格折讓撥備人民幣1.04億元所致。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.